Indo US Bio-Tech Ltd

For the fifth straight session, Indo US Bio-Tech Ltd closed lower, breaching its 52-week low at Rs 94 on 3 Jun 2026, marking a 6.42% decline over the last three days and underperforming its sector by 2.46% today alone.

Indo US Bio-Tech Ltd., a micro-cap agricultural products company with a market capitalisation of ₹201.00 crores, reported a challenging fourth quarter for FY26, with net profit declining sharply to ₹1.97 crores from ₹3.00 crores in Q3 FY26, marking a 34.33% sequential decline. On a year-on-year basis, the profit contraction was even steeper at 46.47% compared to ₹3.68 crores in Q4 FY25. The stock, currently trading at ₹100.45, has struggled significantly over the past year, declining 41.45% whilst the broader market fell just 8.40%, underscoring deep investor concerns about the company's operational trajectory.

Indo US Bio-Tech Ltd is rated Sell by MarketsMOJO, with this rating last updated on 19 Jan 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 29 May 2026, providing investors with an up-to-date view of the stock’s fundamentals, returns, and market performance.

Indo US Bio-Tech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 19 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 18 May 2026, providing investors with the latest insights into the company’s performance and outlook.

Indo US Bio-Tech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 19 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 07 May 2026, providing investors with the latest insights into the company’s performance and outlook.

Indo US Bio-Tech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 19 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 26 April 2026, providing investors with the latest insights into the company’s performance and outlook.

Indo US Bio-Tech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 19 January 2026. However, the analysis and financial metrics presented here reflect the company’s current position as of 15 April 2026, providing investors with an up-to-date view of its fundamentals, returns, and overall outlook.

Indo US Bio-Tech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 19 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 April 2026, providing investors with the latest insights into the company’s performance and outlook.

Indo US Bio-Tech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 19 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 24 March 2026, providing investors with the latest insights into its performance and outlook.

Indo US Bio-Tech Ltd, a micro-cap player in the Other Agricultural Products sector, has touched a fresh 52-week low of Rs.95 today, marking a significant decline in its stock price amid broader market pressures and company-specific performance issues.

Indo US Bio-Tech Ltd’s stock declined to a fresh 52-week low of Rs.96 on 13 Mar 2026, marking a significant drop amid a broader sectoral slump and subdued market conditions. The stock’s performance reflects ongoing pressures within the Other Agricultural Products sector, which has seen a notable downturn over recent months.

Indo US Bio-Tech Ltd’s shares touched a new 52-week low of Rs.96.9 today, marking a significant decline amid a broader market downturn. The stock has been on a downward trajectory for five consecutive sessions, shedding 28.58% in returns during this period, reflecting ongoing pressures within the Other Agricultural Products sector.

Indo US Bio-Tech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 19 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 12 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Indo US Bio-Tech Ltd’s stock declined to a fresh 52-week low of Rs.97.65 today, marking a significant milestone in its ongoing downward trajectory. The stock has underperformed both its sector and broader market indices, reflecting a combination of recent quarterly results and longer-term performance trends.

Indo US Bio-Tech Ltd, a key player in the Other Agricultural Products sector, has seen a significant shift in its valuation parameters, moving from an attractive to a very attractive rating. Despite a sharp decline in its share price and a downgrade in its overall mojo grade to Sell, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now present a compelling case for value investors seeking opportunities in a volatile market.

Indo US Bio-Tech Ltd, a player in the Other Agricultural Products sector, has declined to a fresh 52-week low of Rs.104.85 on 9 Mar 2026, marking a significant downturn amid broader market volatility and sectoral weakness.

Indo US Bio-Tech Ltd is rated Sell by MarketsMOJO, with this rating last updated on 19 January 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 26 February 2026, providing investors with the most recent and relevant data to assess the company’s outlook.

Indo US Bio-Tech Ltd, a key player in the Other Agricultural Products sector, has recently experienced a notable shift in its valuation parameters, moving from an attractive to a fair rating. This change reflects evolving market perceptions amid fluctuating price-to-earnings (P/E) and price-to-book value (P/BV) ratios, alongside comparisons with industry peers and historical benchmarks. Investors are now reassessing the stock’s price attractiveness in light of these developments.